Compugen to Present Cancer Immunotherapy Targets at Two Tumor Immunology Conferences This Month

Compugen Ltd. (NASDAQ: CGEN) today announced that it will present aspects of its immune checkpoint related research at two scientific conferences this month.

On February 9, Arthur Machlenkin, PhD, Head of Immunology Group at Compugen, will deliver an oral presentation at the Keystone Symposia: Tumor Immunology - Multidisciplinary Science Driving Combination Therapy being held from February 8-13, in Banff, Canada. In his talk titled Identification of Novel Immuno-Modulatory Targets for Cancer Immunotherapy, Dr. Machlenkin will discuss Compugen’s discovery approach in identifying 11 novel immune checkpoint candidates for cancer immunotherapy. In addition, Dr. Machlenkin will present experimental data demonstrating the immunomodulatory function and expression patterns of two Compugen-discovered immune checkpoints: CGEN-15049 and CGEN-15027.

On February 16, Ofer Levy, PhD, Principal Scientist at Compugen, will deliver a presentation titled Computational Discovery and Experimental Validation of Novel Players in the Immuno-Oncology Arena at the Onco-Immunology Meeting: Prospects of Immunity for Precision Cancer Medicine, to be held at the Israel Institute of Advanced Studies, in Jerusalem, Israel. In his talk Dr. Levy will give an overview on the design and implementation of immune assays aimed at exploring the potential role of Compugen’s novel targets as immune checkpoint candidates.

About Compugen

Compugen is a leading drug discovery company focused on monoclonal antibodies and therapeutic proteins to address important unmet needs in the fields of oncology and immunology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of novel drug target candidates, which are then advanced in its Pipeline Program. The discovery and development of monoclonal antibody therapeutic candidates against selected Compugen-discovered novel target candidates is performed by Compugen’s wholly-owned U.S. subsidiary located in South San Francisco. The Company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. For additional information, please visit Compugen's corporate website at www.cgen.com.

Forward Looking Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as “will,” “may,” “expects,” “anticipates,” “believes,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these and other factors are discussed in the "Risk Factors" section of Compugen’s most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission as well as other documents that may be subsequently filed by Compugen from time to time with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.